These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1304 related items for PubMed ID: 31033434

  • 1. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
    Ramanan AV, Dick AD, Jones AP, Hughes DA, McKay A, Rosala-Hallas A, Williamson PR, Hardwick B, Hickey H, Rainford N, Hickey G, Kolamunnage-Dona R, Culeddu G, Plumpton C, Wood E, Compeyrot-Lacassagne S, Woo P, Edelsten C, Beresford MW.
    Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
    [Abstract] [Full Text] [Related]

  • 2. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).
    Ramanan AV, Dick AD, Benton D, Compeyrot-Lacassagne S, Dawoud D, Hardwick B, Hickey H, Hughes D, Jones A, Woo P, Edelsten C, Beresford MW, SYCAMORE Trial Management Group.
    Trials; 2014 Jan 09; 15():14. PubMed ID: 24405833
    [Abstract] [Full Text] [Related]

  • 3. Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis.
    Hughes DA, Culeddu G, Plumpton CO, Wood E, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot Lacassagne S, Hardwick B, Hickey H, Woo P, Beresford MW, Ramanan AV.
    Ophthalmology; 2019 Mar 09; 126(3):415-424. PubMed ID: 30336181
    [Abstract] [Full Text] [Related]

  • 4. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.
    Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW, SYCAMORE Study Group.
    N Engl J Med; 2017 Apr 27; 376(17):1637-1646. PubMed ID: 28445659
    [Abstract] [Full Text] [Related]

  • 5. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J, Cooper K, Harris P, Picot J, Rose M.
    Health Technol Assess; 2016 Apr 27; 20(34):1-222. PubMed ID: 27135404
    [Abstract] [Full Text] [Related]

  • 6. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.
    Tikhonova IA, Yang H, Bello S, Salmon A, Robinson S, Hemami MR, Dodman S, Kharechko A, Haigh RC, Jani M, McDonald TJ, Hoyle M.
    Health Technol Assess; 2021 Feb 27; 25(8):1-248. PubMed ID: 33555998
    [Abstract] [Full Text] [Related]

  • 7. Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT.
    Batchelor JM, Thomas KS, Akram P, Azad J, Bewley A, Chalmers JR, Cheung ST, Duley L, Eleftheriadou V, Ellis R, Ferguson A, Goulding JM, Haines RH, Hamad H, Ingram JR, Laguda B, Leighton P, Levell N, Makrygeorgou A, Meakin GD, Millington A, Ogboli M, Rajasekaran A, Ravenscroft JC, Rogers A, Sach TH, Santer M, Stainforth J, Tan W, Wahie S, White J, Whitton ME, Williams HC, Wright A, Montgomery AA.
    Health Technol Assess; 2020 Nov 27; 24(64):1-128. PubMed ID: 33245043
    [Abstract] [Full Text] [Related]

  • 8. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis.
    Quartier P, Baptiste A, Despert V, Allain-Launay E, Koné-Paut I, Belot A, Kodjikian L, Monnet D, Weber M, Elie C, Bodaghi B, ADJUVITE Study Group.
    Ann Rheum Dis; 2018 Jul 27; 77(7):1003-1011. PubMed ID: 29275333
    [Abstract] [Full Text] [Related]

  • 9. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults.
    Squires H, Poku E, Bermejo I, Cooper K, Stevens J, Hamilton J, Wong R, Denniston A, Pearce I, Quhill F.
    Health Technol Assess; 2017 Nov 27; 21(68):1-170. PubMed ID: 29183563
    [Abstract] [Full Text] [Related]

  • 10. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
    Foeldvari I, Becker I, Horneff G.
    Arthritis Care Res (Hoboken); 2015 Nov 27; 67(11):1529-35. PubMed ID: 25988824
    [Abstract] [Full Text] [Related]

  • 11. Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis.
    Renton WD, Jung J, Palestine AG.
    Cochrane Database Syst Rev; 2022 Oct 14; 10(10):CD013818. PubMed ID: 36239193
    [Abstract] [Full Text] [Related]

  • 12. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S, Everett CC, Naraghi K, Davies C, Dawkins B, Hulme C, McCabe C, Pavitt S, Emery P, Sharples L, Buch MH.
    Health Technol Assess; 2018 Jun 14; 22(34):1-280. PubMed ID: 29900829
    [Abstract] [Full Text] [Related]

  • 13. Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE Trial.
    Horton S, Jones AP, Guly CM, Hardwick B, Beresford MW, Lee RW, Dick AD, Ramanan AV.
    Am J Ophthalmol; 2019 Nov 14; 207():170-174. PubMed ID: 31201796
    [Abstract] [Full Text] [Related]

  • 14. Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT.
    Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, Wood J, Raynes K, Higgins H, Dawkins B, Meads D, Hulme CT, Whittaker AC, Hawkey P, Low E, Dunn JA.
    Health Technol Assess; 2019 Nov 14; 23(62):1-94. PubMed ID: 31690402
    [Abstract] [Full Text] [Related]

  • 15. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G, Cotton S, Fielding S, McMeekin N, Barnes PJ, Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, Soyza A, Gompertz S, Haughney J, Innes K, Kaniewska J, Lee A, Morice A, Norrie J, Sullivan A, Wilson A, Price D.
    Health Technol Assess; 2019 Jul 14; 23(37):1-146. PubMed ID: 31343402
    [Abstract] [Full Text] [Related]

  • 16. Methotrexate for juvenile idiopathic arthritis.
    Tan J, Renton WD, Whittle SL, Takken T, Johnston RV, Tiller G, Munro J, Buchbinder R.
    Cochrane Database Syst Rev; 2024 Feb 09; 2(2):CD003129. PubMed ID: 38334147
    [Abstract] [Full Text] [Related]

  • 17. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
    Webb NJ, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Wheatley K, Ives NJ.
    Health Technol Assess; 2019 May 09; 23(26):1-108. PubMed ID: 31156083
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
    Gilson R, Nugent D, Bennett K, Doré CJ, Murray ML, Meadows J, Haddow LJ, Lacey C, Sandmann F, Jit M, Soldan K, Tetlow M, Caverly E, Nathan M, Copas AJ.
    Health Technol Assess; 2020 Sep 09; 24(47):1-86. PubMed ID: 32975189
    [Abstract] [Full Text] [Related]

  • 20. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).
    Ramanan AV, Guly CM, Keller SY, Schlichting DE, de Bono S, Liao R, Quartier P.
    Trials; 2021 Oct 09; 22(1):689. PubMed ID: 34627340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.